Kwarlay.com

Navigating the News Maze with Clarity

Medicine

FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Winrevair is the first FDA-approved activin signaling inhibitor therapy for pulmonary arterial hypertension.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *